Studies have found that in tumor immunity, CD4+ T cells can activate CD8+ T cells through various mechanisms after being activated to differentiate into cytotoxic T-lymphocytes, while maintaining and enhancing their anti-tumor response. This evidence concerns the gene CD8A and neoplasm.